Qiagen (NASDAQ:QGEN) posted its quarterly earnings results on Monday. The company reported $0.35 EPS for the quarter, topping the Zacks’ consensus estimate of $0.33 by $0.02, MarketWatch Earnings reports. Qiagen had a return on equity of 11.74% and a net margin of 2.85%. The firm had revenue of $377.90 million during the quarter, compared to analyst estimates of $380.11 million. During the same period last year, the company earned $0.32 earnings per share. The business’s revenue for the quarter was up 3.8% on a year-over-year basis.
NASDAQ:QGEN opened at $33.54 on Tuesday. Qiagen has a 52-week low of $30.20 and a 52-week high of $39.45. The company has a current ratio of 5.07, a quick ratio of 4.59 and a debt-to-equity ratio of 0.69.
QGEN has been the subject of a number of analyst reports. BidaskClub lowered Qiagen from a “hold” rating to a “sell” rating in a report on Thursday, September 13th. Morgan Stanley raised their price target on Qiagen from $37.00 to $38.00 and gave the stock an “overweight” rating in a report on Wednesday, August 1st. Commerzbank reaffirmed a “buy” rating on shares of Qiagen in a report on Wednesday, August 29th. Barclays reaffirmed a “buy” rating and issued a $43.00 price target on shares of Qiagen in a report on Thursday, September 6th. Finally, Deutsche Bank reaffirmed a “buy” rating on shares of Qiagen in a report on Friday, August 3rd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $38.88.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.